OvaScience Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Leerink Partners Remains Sidelined on OvaScience (OVAS) Following 1Q
May 6, 2016 8:45 AM EDTLeerink Partners reiterated a Market Perform rating on OvaScience (NASDAQ: OVAS), and raised the price target to $7.00 (from $6.00), following the company's 1Q earnings report. OVAS reported EPS of ($0.80) which was below Leerink Partners' estimate of ($0.75). The weakness in EPS was due to higher than expected COGS and R&D... More
OvaScience (OVAS) Misses Q1 EPS by 8c
May 5, 2016 4:01 PM EDTOvaScience (NASDAQ: OVAS) reported Q1 EPS of ($0.80), $0.08 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $146 thousand versus the consensus estimate of $110 thousand.
"OvaScience is currently focused on building our operational platform to support the expansion of the AUGMENT... More
